Substituted imidazo[1,5-a]pyrazines as Btk inhibitors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 7, 2018
Grant Date -
Jan 11, 2018
app pub date -
Dec 17, 2015
filing date -
Dec 31, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Calculated Rating
|
US Family Size
|
Non-US Coverage
|
Abstract
The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, Formula (I) or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula I in the treatment of Btk mediated disorders.
First Claim
Other Claims data not available
Family
+
−
| Country | kind | publication No. | Filing Date |
|---|---|---|---|
| WO | A1 | WO2016106626 | Dec 31, 2014 |
| WO | A1 | WO2016109220 | Dec 17, 2015 |
| EP | B1 | EP3240536 | Dec 17, 2015 |
International Classification(s)
- 2015 Application Filing Year
- A61K Class
- 16157 Applications Filed
- 11882 Patents Issued To-Date
- 73.55 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 7 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Feb 7, 2026 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 7, 2030 |
